The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Adaptive Sampling Advances Pediatric Cancer Profiling
Oncology Omics Precision medicine Research and Innovations Molecular Pathology

Adaptive Sampling Advances Pediatric Cancer Profiling

Rapid nanopore sequencing identifies cancer mutations within hours, offering a potential alternative to multiple diagnostic tests

11/16/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

5 Key Takeaways
  • 1

    Researchers evaluated adaptive sampling whole-genome sequencing in 36 samples from 35 pediatric patients, including 31 tumor samples.

  • 2

    Compared with conventional testing, the assay detected all 20 known gene fusions, mutations in 58 of 59 affected genes, and 20 of 21 large copy-number alterations.

  • 3

    Within 24 hours, all 20 gene fusions and 47 mutations with variant allele frequencies above 25% had at least five supporting reads; large chromosomal alterations appeared within an hour.

  • 4

    Methylation analysis correctly classified 9 of 11 acute lymphoblastic leukemia samples and 8 of 12 solid tumors, without separate testing.

  • 5

    Estimated sequencing costs were approximately CAD $1,700 per sample versus more than CAD $5,000 for combined conventional approaches; further clinical validation is needed.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.